TriSalus Life Sciences (TLSI) Set to Announce Earnings on Tuesday

TriSalus Life Sciences (NASDAQ:TLSI) is expected to announce its Q3 2026 results after the market closes on Tuesday, November 10th. Analysts expect the company to post earnings of ($0.14) per share and revenue of $14.02 million for the quarter. Parties are encouraged to explore the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Tuesday, November 10, 2026 at 8:30 AM ET.

TriSalus Life Sciences (NASDAQ:TLSI) last announced its quarterly earnings data on Thursday, August 6th. The company reported ($0.16) EPS for the quarter, hitting the consensus estimate of ($0.16). The company had revenue of $11.41 million during the quarter, compared to the consensus estimate of $10.27 million. On average, analysts expect TriSalus Life Sciences to post ($0.53) EPS for the current fiscal year and ($0.28) EPS for the next fiscal year.

TriSalus Life Sciences Stock Performance

NASDAQ:TLSI traded down $0.07 during trading hours on Tuesday, reaching $3.56. The stock had a trading volume of 35,097 shares, compared to its average volume of 291,148. The company has a debt-to-equity ratio of 5.05, a quick ratio of 4.97 and a current ratio of 5.35. The stock has a 50 day simple moving average of $4.40 and a 200 day simple moving average of $4.41. TriSalus Life Sciences has a 12-month low of $2.20 and a 12-month high of $7.95. The stock has a market cap of $219.45 million, a P/E ratio of -2.70 and a beta of 0.50.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on TLSI. Wall Street Zen upgraded shares of TriSalus Life Sciences from a “sell” rating to a “hold” rating in a research note on Sunday, August 23rd. Guggenheim set a $12.00 price target on shares of TriSalus Life Sciences in a research note on Wednesday, September 23rd. Stifel Nicolaus set a $12.00 price objective on shares of TriSalus Life Sciences in a report on Wednesday, September 23rd. HC Wainwright raised their price objective on shares of TriSalus Life Sciences from $11.00 to $12.00 and gave the stock a “buy” rating in a report on Wednesday, September 23rd. Finally, Zacks Research upgraded shares of TriSalus Life Sciences to a “hold” rating in a research note on Thursday, September 10th. Three research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $10.20.

TriSalus Life Sciences Company Profile

TriSalus Life Sciences is an oncology-focused healthcare company developing technologies and therapies for patients with liver and pancreatic tumors. The company combines medical devices, drug-delivery systems and immunotherapy programs to address tumors that may be difficult to treat with conventional approaches.

Its core technology is Pressure-Enabled Drug Delivery (PEDD), a platform designed to improve the delivery of therapeutic agents directly to tumors through the arterial blood supply.